{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:25:53Z","timestamp":1776353153057,"version":"3.51.2"},"reference-count":15,"publisher":"Informa Healthcare","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2014,11,1]]},"DOI":"10.1185\/03007995.2014.941976","type":"journal-article","created":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T17:05:22Z","timestamp":1407517522000},"page":"2305-2315","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Population pharmacokinetics and pharmacokinetics\/pharmacodynamics of bendamustine in pediatric patients with relapsed\/refractory acute leukemia"],"prefix":"10.1185","volume":"30","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[{"name":"Sci-Med Bridge LLC\rMalvern, PAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Megason","sequence":"additional","affiliation":[{"name":"University of Mississippi\rJackson, MSUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Bond","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D Inc. Frazer, PAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Hellriegel","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D Inc. West Chester, PAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Philmore","family":"Robertson","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D Inc. West Chester, PAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus","family":"Grasela","sequence":"additional","affiliation":[{"name":"Cognigen Corporation\rBuffalo, NYUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luann","family":"Phillips","sequence":"additional","affiliation":[{"name":"Cognigen Corporation\rBuffalo, NYUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2014,8,11]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8389"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"CIT0005","unstructured":"Treanda [package insert]. Frazer, PA, USA: Teva Pharmaceutical Industries Ltd, 2013"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2011.03.002"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1254-8"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"CIT0009","first-page":"1357","volume":"90","author":"Bergmann MA","year":"2006","journal-title":"Haematologica"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0074-4"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000175587.31940.19"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.09.029"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0331-8"},{"key":"CIT0014","doi-asserted-by":"crossref","unstructured":"Fraser C, Brown P, Megason G, et al. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability. J Pediatr Hematol Oncol 2014;36:e212-8","DOI":"10.1097\/MPH.0000000000000021"},{"key":"CIT0015","unstructured":"Teva Branded Pharmaceutical Products R&D Inc. Data on file. Population pharmacokinetic\/pharmacodynamic report. Population pharmacokinetic and pharmacokinetic\/pharmacodynamic evaluations of bendamustine HCl monotherapy in pediatric patients. Cephalon Report No. CP-11-002. Frazer, PA: Teva Branded Pharmaceutical Products R&D Inc., December 2011"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2014.941976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T03:17:59Z","timestamp":1598757479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2014.941976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11,1]]}},"alternative-id":["10.1185\/03007995.2014.941976"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2014.941976","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}